secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2025-12-01T23:59:59+00:00
Accession:  0001517022-25-000051
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia buys ADX-097 from Q32 Bio for $10M upfront (total up to $582M milestones); plans Phase 2 trials in 2026
--------------------------------------------------------------------------------

- Upfront $7M paid at closing, additional $3M due in 6 months; development milestones up to $94.5M and commercial milestones up to $487.5M, plus tiered royalties from low single to mid-teen %.
- AKB-097 is a tissue-targeted C3d-Factor H fusion protein complement inhibitor; Phase 2 basket trial in multiple rare kidney diseases planned to start treating subjects in 2026.
- Praliciguat (sGC stimulator) Phase 2 trial initiated in FSGS; additional rare podocytopathy indications planned.
- Existing cash resources plus cash from operations expected to fund current operating plan for at least 2 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702225000051/0001517022-25-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702225000051/akba-20251128.htm
  HTML page:      https://secwatch.observer/filing/0001517022-25-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer